What is Beta Drugs Ltd (BETA) share price return in the past 10 years?

Data is not available for this company

What is the share price of Beta Drugs Ltd (BETA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Beta Drugs Ltd (BETA) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Beta Drugs?

The latest standalone P/E ratio of Beta Drugs as of 01-Jan-1970 is 113.82.

What is the P/B ratio of Beta Drugs Ltd (BETA)?

The latest standalone P/B ratio of Beta Drugs Ltd (BETA) as of 01-Jan-1970 is 10.84.

What is the 52-week high and low of Beta Drugs Ltd (BETA)?

The 52-week high of Beta Drugs Ltd (BETA) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Beta Drugs Ltd (BETA) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Beta Drugs Ltd (BETA)
Brand: Beta Drugs

Beta Drugs Ltd (BETA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BETA Pharmaceuticals & Drugs | Small Cap | Beta Drugs Share Price

Beta Drugs Ltd (BETA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BETA Pharmaceuticals & Drugs | Small Cap | Beta Drugs Share Price

Key Metrics

Valuation Multiples

Market Cap

₹1,632 Cr.

Current Price

₹0

52-Week Low / High

₹0 / 0

TTM EPS

₹12.9

TTM Sales

₹225 Cr.

Book Value per Share

₹135.8

P/E Ratio

113.82

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

10.84

In line with its 5-year historical median

Price to Sales (P/S)

7.24

Higher than its 5-year historical median

EV/EBITDA

41.41

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

12.60%

Outperforms industry median

Return on Capital Employed (ROCE)

13.53%

Outperforms industry median

Return on Assets (ROA)

6.21%

Operating Profit Margin

14.3%

Net Profit Margin

7.01%

Gross Profit Margin

14.9%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

11.43%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-6.29%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-29.67%

Asset Quality

Promoter Holding

64.63%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹139 Cr.

Equity

₹11.1 Cr.

Face Value

₹10

All Time Low / High

- / -

Beta Drugs stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Beta Drugs Ltd a good quality company?

Beta Drugs Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Beta Drugs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Beta Drugs Ltd vs industry peers?

Beta Drugs Ltd revenue CAGR is 27.51%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Beta Drugs Ltd?

Promoters hold 64.63% of the Beta Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Beta Drugs Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 33.83% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	21.9%	48.9%	28.6%	18.4%	16.9%	15.9%	26.9%	27.9%	27.3%	13.5%	-
Value Creation Index ⓘ	0.6	2.5	1.1	0.3	0.2	0.1	0.9	1.0	1.0	0.0	-
Growth Parameters ⓘ
Sales ⓘ	26.4	41.7	50.6	58.1	65.3	79.5	125	158	198	220	225
Sales YoY Gr.	-	57.9%	21.4%	14.8%	12.5%	21.7%	57.1%	26.5%	25.2%	11.4%	-
Adj EPS ⓘ	1.8	7.4	8.1	8.8	7	6.9	14.1	18.6	21.7	18.5	12.9
YoY Gr.	-	308.8%	9.3%	8.5%	-20.2%	-1.3%	104.1%	32%	16.6%	-15.1%	-
BVPS (₹) ⓘ	3.5	9.7	36.2	44.7	55.9	62.8	76.7	95.4	114.9	127.8	135.8
Adj Net Profit ⓘ	1.1	4.6	7.4	8	7.1	7	14.3	18.8	21.9	18.6	14
Cash Flow from Ops. ⓘ	-0.4	4.7	17.1	7.7	6.1	11.6	18.8	10.2	21.2	18	-
Debt/CF from Ops. ⓘ	-22.5	1.7	0.5	1	1.5	0.5	0.4	0.6	0.3	7.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26.6%	27.5%	20.8%	11.4%
Adj EPS ⓘ	29.4%	21.4%	9.4%	-15.1%
BVPSⓘ	49.1%	18%	18.5%	11.2%
Share Price	-	36.6%	23.9%	-19.6%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	69.4	112	37.7	21.7	14.6	11.7	20.2	21.7	20.7	15.2	9.8
Op. Profit Mgn % ⓘ	11.4	18.7	20.4	18.4	18	19.3	20.2	19.8	17	14.3	13.2
Net Profit Mgn % ⓘ	4.3	11.1	14.5	13.7	10.8	8.8	11.4	11.9	11.1	8.5	6.4
Debt to Equity ⓘ	3.8	1.4	0.2	0.2	0.2	0.1	0.1	0.1	0.1	1	0.8
Working Cap Days ⓘ	65	99	138	180	211	196	149	157	170	187	187
Cash Conv. Cycle ⓘ	2	26	47	63	73	66	41	49	51	46	141

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	26	42	51	58	65	79	125	158	198	220
Operating Expenses ⓘ +	23	34	41	48	54	64	100	127	164	189
Manufacturing Costs	0	1	6	7	8	9	12	15	17	22
Material Costs	15	24	27	30	35	43	71	83	112	120
Employee Cost	3	4	1	2	4	5	7	10	11	15
Other Costs ⓘ	5	5	6	8	7	7	10	18	24	32
Operating Profit ⓘ	3	7	9	10	12	15	25	31	34	31
Operating Profit Margin (%)	11.4%	17.5%	18.7%	17.8%	18.0%	19.3%	20.2%	19.8%	17.0%	14.3%
Other Income ⓘ +	0	0	0	0	0	1	1	1	2	6
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	-5
Interest ⓘ	1	1	1	1	1	1	0	1	1	5
Depreciation ⓘ	1	1	2	2	3	5	5	6	5	7
Profit Before Tax ⓘ	1	5	7	7	9	10	20	25	29	21
Tax ⓘ	0	1	0	-0	2	3	6	6	8	5
Profit After Tax	1	4	7	8	7	7	14	19	22	15
PAT Margin (%)	4.3%	10.3%	13.4%	13.3%	10.9%	8.8%	11.4%	11.9%	11.1%	7.0%
Adjusted EPS (₹)	1.8	6.8	7.5	8.5	7.0	6.9	14.1	18.6	21.7	15.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Beta Drugs - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	2	6	33	41	56	63	77	96	116	129
Share Capital ⓘ	1	1	9	9	10	10	10	10	10	10
Reserves ⓘ	1	5	24	32	47	54	68	87	106	119
Debt +	8	8	6	6	7	4	5	4	4	124
Long Term Debt	4	4	3	5	3	3	5	4	4	124
Short Term Debt	4	4	4	1	4	1	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	7	6	10	9	13	20	23	36	41
Others Liabilities ⓘ	1	3	4	9	10	8	12	14	20	28
Total Liabilities ⓘ	15	23	50	66	83	89	115	137	175	321
Fixed Assets
Net Fixed Assets ⓘ +	7	8	13	12	32	28	34	35	36	53
Gross Block	9	11	18	19	42	43	54	60	65	90
Accumulated Depreciation	2	3	5	7	10	15	20	25	29	36
CWIP ⓘ	0	0	1	15	0	2	0	0	0	0
Investments ⓘ	0	0	0	2	6	7	7	7	6	6
Inventories	3	2	3	6	6	8	8	14	22	27
Trade Receivables	4	11	14	17	21	21	31	44	50	49
Cash Equivalents ⓘ	0	0	12	3	4	8	16	18	27	142
Others Assets ⓘ	0	2	6	10	14	15	19	21	33	44
Total Assets ⓘ	15	23	50	66	83	89	115	137	175	321

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0	5	17	8	6	12	19	10	21	18
PBT ⓘ	1	5	7	7	9	10	20	25	29	25
Adjustment ⓘ	2	2	15	2	2	4	3	0	-6	-8
Changes in Working Capital ⓘ	-3	-3	-5	-1	-4	-2	-5	-15	-2	0
Tax Paid ⓘ	-0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-2	-2	-11	-16	-14	-3	-13	-6	-11	-21
Capex	-2	-2	-8	-15	-8	-3	-10	-7	-6	-24
Net Investments	0	0	0	-2	-5	-0	0	-0	1	0
Others ⓘ	0	0	-3	0	-2	1	-3	1	-5	3
Cash Flow From Financing Activity ⓘ +	3	-3	5	-1	9	-4	1	-2	-1	118
Net Proceeds from Shares ⓘ	0	0	8	0	9	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	-1	-1	3	-1	-0	2	-1	0	123
Interest Paid ⓘ	-1	-1	-1	-1	-1	-1	-0	-1	-1	-5
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	3	-1	-0	-2	3	-3	-1	0	0	-0
Net Cash Flow ⓘ	0	0	12	-9	1	4	7	2	9	115

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	69.39	103.22	34.73	21	14.63	11.64	20.23	21.66	20.67	12.6
ROCE (%)	21.91	48.91	28.63	18.42	16.85	15.91	26.91	27.93	27.27	13.53
Asset Turnover Ratio	2.27	2.17	1.39	1.01	0.88	0.92	1.23	1.26	1.27	0.89
PAT to CFO Conversion(x)	-0	1.25	2.43	1	0.86	1.71	1.36	0.53	0.95	1.2
Working Capital Days
Receivable Days	31	65.40	90.10	99.90	106.80	95.80	76.30	86.60	86.90	82.10
Inventory Days	28.60	23	18.80	29	35	31.70	23.60	25.60	32.90	40.90
Payable Days	74.60	85	88.40	97.50	101.90	94.60	84.90	93.90	95.90	116.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Beta Drugs Ltd FAQs

The current trading price of Beta Drugs on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Beta Drugs stood at ₹1,631.5 Cr

The latest P/E ratio of Beta Drugs as of 31-Dec-1969 is 113.8.

The latest P/B ratio of Beta Drugs as of 31-Dec-1969 is 10.84.

The 52-week high of Beta Drugs is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beta Drugs is ₹225 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company.

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Beta Drugs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Beta Drugs Ltd

No data to display

Beta Drugs Ltd (BETA)

Beta Drugs Ltd (BETA)

Beta Drugs stock performance